×
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
NASDAQ:LOGC

LogicBio Therapeutics Stock Forecast, Price & News

$0.40
+0.05 (+14.43%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.35
$0.41
50-Day Range
$0.35
$0.67
52-Week Range
$0.34
$5.15
Volume
303,752 shs
Average Volume
830,212 shs
Market Capitalization
$13.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

LogicBio Therapeutics Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
2,369.1% Upside
$10.00 Price Target
Short Interest
Healthy
0.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.49
Upright™ Environmental Score
News Sentiment
1.44mentions of LogicBio Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.04) to ($1.17) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.22 out of 5 stars

Medical Sector

785th out of 1,429 stocks

Biological Products, Except Diagnostic Industry

126th out of 217 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive LOGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LogicBio Therapeutics logo

About LogicBio Therapeutics (NASDAQ:LOGC)

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

LOGC Stock News Headlines

LogicBio Therapeutics Inc - Stock Quote LOGC
LogicBio Says FDA Lifts Clinical Hold On LB-001 IND
Clinical Development Update from Portfolio Company LogicBio
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LOGC
Fax
N/A
Employees
62
Year Founded
N/A

Company Calendar

Last Earnings
5/16/2022
Today
7/01/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+2,422.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-40.03 million
Net Margins
-468.89%
Pretax Margin
-469.25%

Debt

Sales & Book Value

Annual Sales
$5.41 million
Book Value
$0.93 per share

Miscellaneous

Free Float
30,722,000
Market Cap
$13.07 million
Optionable
Not Optionable
Beta
1.49














LogicBio Therapeutics Frequently Asked Questions

Should I buy or sell LogicBio Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LogicBio Therapeutics stock.
View analyst ratings for LogicBio Therapeutics
or view top-rated stocks.

What is LogicBio Therapeutics' stock price forecast for 2022?

4 brokers have issued 1 year target prices for LogicBio Therapeutics' stock. Their LOGC stock forecasts range from $6.00 to $16.00. On average, they predict LogicBio Therapeutics' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 2,422.1% from the stock's current price.
View analysts' price targets for LogicBio Therapeutics
or view top-rated stocks among Wall Street analysts.

How has LogicBio Therapeutics' stock performed in 2022?

LogicBio Therapeutics' stock was trading at $2.31 at the beginning of 2022. Since then, LOGC stock has decreased by 82.8% and is now trading at $0.3965.
View the best growth stocks for 2022 here
.

When is LogicBio Therapeutics' next earnings date?

LogicBio Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for LogicBio Therapeutics
.

How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) posted its earnings results on Monday, May, 16th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.06. The firm had revenue of $2.82 million for the quarter. LogicBio Therapeutics had a negative trailing twelve-month return on equity of 104.61% and a negative net margin of 468.89%.
View LogicBio Therapeutics' earnings history
.

Who are LogicBio Therapeutics' key executives?

LogicBio Therapeutics' management team includes the following people:
  • Mr. Frederic Chereau M.B.A., Pres, CEO & Director (Age 55, Pay $793.2k) (LinkedIn Profile)
  • Dr. Mark A. Kay M.D., Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director (Age 64, Pay $107.5k)
  • Ms. Cecilia Jones, CFO & Treasurer (Age 47, Pay $531.09k)
  • Dr. Daniel J. Gruskin M.D., Chief Medical Officer (Age 50, Pay $577.48k)
  • Dr. Leszek Lisowski M.B.A., Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Adi Barzel Ph.D., Co-Founder
  • Dr. Matthias Hebben Ph.D., Global VP & Head of Technology Devel.
  • Ms. Mariana Nacht Ph.D., Chief Scientific Officer (Age 58)
  • Ms. Andrea Paul, Gen. Counsel & Corp. Sec. (Age 41)
  • Ms. Grace Lochhead, VP & Head of HR

What other stocks do shareholders of LogicBio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Acceleron Pharma (XLRN), Stoke Therapeutics (STOK), Precision BioSciences (DTIL), Micron Technology (MU), Homology Medicines (FIXX) and II-VI (IIVI).

When did LogicBio Therapeutics IPO?

(LOGC) raised $77 million in an IPO on Friday, October 19th 2018. The company issued 5,800,000 shares at a price of $12.50-$14.00 per share. Jefferies, Barclays and William Blair served as the underwriters for the IPO and Chardan was co-manager.

What is LogicBio Therapeutics' stock symbol?

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

How do I buy shares of LogicBio Therapeutics?

Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LogicBio Therapeutics' stock price today?

One share of LOGC stock can currently be purchased for approximately $0.40.

How much money does LogicBio Therapeutics make?

LogicBio Therapeutics (NASDAQ:LOGC) has a market capitalization of $13.07 million and generates $5.41 million in revenue each year. The company earns $-40.03 million in net income (profit) each year or ($1.120010) on an earnings per share basis.

How many employees does LogicBio Therapeutics have?

LogicBio Therapeutics employs 62 workers across the globe.

How can I contact LogicBio Therapeutics?

LogicBio Therapeutics' mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The official website for LogicBio Therapeutics is www.logicbio.com. The company can be reached via phone at (617) 245-0399 or via email at [email protected].

This page (NASDAQ:LOGC) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.